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ABSTRACT
Introduction: There are positive aspects regarding the prescribing of fixed dose combinations (FDCs)
versus prescribing the medicines separately. However, these have to be balanced against concerns
including increased costs and their irrationality in some cases. Consequently, there is a need to review
their value among lower- and middle-income countries (LMICs) which have the greatest prevalence of
both infectious and noninfectious diseases and issues of affordability.
Areas covered: Review of potential advantages, disadvantages, cost-effectiveness, and availability of
FDCs in high priority disease areas in LMICs and possible initiatives to enhance the prescribing of valued
FDCs and limit their use where there are concerns with their value.
Expert commentary: FDCs are valued across LMICs. Advantages include potentially improved response
rates, reduced adverse reactions, increased adherence rates, and reduced costs. Concerns include
increased chances of drug:drug interactions, reduced effectiveness, potential for imprecise diagnoses
and higher unjustified prices. Overall certain FDCs including those for malaria, tuberculosis, and
hypertension are valued and listed in the country’s essential medicine lists, with initiatives needed to
enhance their prescribing where currently low prescribing rates. Proposed initiatives include robust
clinical and economic data to address the current paucity of pharmacoeconomic data. Irrational FDCs
persists in some countries which are being addressed.
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1. Introduction
Fixed dose combinations (FDCs) are defined as a combination
of two or more active ingredients within a single form of
pharmaceutical administration [1–6]. They have been shown
to appreciably reduce the risk of medication non-adherence,
which is particularly important in patients with chronic dis-
eases [7]. However, their rationality for use should be based on
sound medical principles as there have been concerns with
their irrationality and utility in several countries [1,2,4,5,8].
We will present concerns in more detail in Section 1.1.
However, these concerns have to be balanced against the
potential advantages of FDCs including their cost-
effectiveness in certain situations. These advantages will be
discussed in detail in Section 1.2 before debating potential
ways forward to enhance the prescribing and funding of
valued FDCs. Alongside this, limit authorization, utilization,
and funding for medically irrational FDCs and/or FDCs of
perceived limited value.
1.1. General concerns with FDCs especially among
lower- and middle-income countries (LMICs)
Concerns with FDCs include potentially altering the optimal dos-
ing of one or more of the components due to differences in
pharmacokinetic profiles and half-lives of the various constituents
[1]. FDCs may also increase the chances of adverse drug reactions
or drug:drug interactions due to the different profiles of the
medicines in the FDC as well as not fully recognizing the differ-
ences that can occur in the pharmacogenetic profiles of patients
during the development of FDCs [1,6,9,10]. Pharmacogenetic con-
cerns are particularly important in FDCswhen the components are
either an essential part of the primary pathway for eliminating the
medicines of interest or a critical step in their onset of action [6].
The pharmacokinetic profiles of the constituents in FDCs are also
important in patients with infectious diseases as there can be
concerns with resistance development due to the combination
[11,12]. Additionally, pharmacokinetic and pharmacodynamic
considerations of the constituents are important in the elderly
where safety profiles may be altered [13]. Evidence has also
shown that inappropriately manufactured FDCs can result in
their reduced effectiveness or enhanced toxicity in routine clinical
care as well as peak effectiveness at different times alongside
concerns with their shelf life [14].
Additional concerns with FDCs include potentially higher
prices than the sum of the individual components unless
justified, higher prices maintained with additional patent
protection, difficulty in ascertaining which component is
responsible for any side-effects that may arise, and patients
may receive too little or too much of a specific ingredient
due to challenges with dose adjustments. Besides this, FDCs
can encourage an imprecise diagnosis especially for patients
with infections and there can be a loss of effectiveness if
patients forget to take their FDC as opposed to just one of
the individual components [1,5,6,15–18]. There are futher-
more concerns that FDCs may become too large impeding
oral administration [13,19].
Article Highlights
● Fixed dose combinations (FDCs) are welcomed across countries illu-
strated by endorsement from the World Health Organisation
● However there are concerns including their rationality, potential to
increase adverse drug reactions, dosing schedules with peak effec-
tiveness at different times, lack of titration and potentially higher
prices
● There is a paucity of data among low- and middle-income countries
assessing their value and cost-effectiveness in routine clinical care
affecting availability and funding
● Perceived benefits regarding FDCs among senior-level personnel
working in LMICs include simplifying the treatment schedule – espe-
cially important in complex disease areas, improved adherence rates
and tolerability, reduced overall costs and reduced chances of stock-
outs
● Additional perceived concerns include the potential for overtreatment
if physicians and patients are not fully aware of their constituents,
potential to increase polypharmacy and missed doses have a greater
impact on subsequent patient care
● Initiatives to enhance the prescribing and dispensing of FDCs where
valued include physician and patient education, developing quality
indicators around their use, accelerating their registration and com-
panies having realistic pricing expectations
● Possible initiatives to reduce or negate the availability of FDCs where
there are concerns include a requirement for companies seeking
registration to provide robust health technology assessment data to
support the application as well as improved physician education and
greater interaction with national patient organisations
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However, some of the perceived difficulties and concerns
with FDCs can potentially be addressed through having multi-
ple formulations available for titration purposes, starting FDCs
only when deemed safe to do so, and/or addressing pharma-
cogenetic and pharmacokinetic concerns during FDC develop-
ment [5,6,20,21]. Alongside this, look to re-formulate large
FDCs with dissolving and other formulations [13,22]. The avail-
ability of multiple formulations was particularly important for
FDCs containing inhaled corticosteroids (ICS) and long-acting
beta-agonists (LABAs) for treating patients with asthma when
health authorities, particularly among Western countries, were
looking to reduce the doses of steroids in the ICS/LABA FDCs
for long-term safety reasons [23]. The lack of different formu-
lations of ICS/LABA FDCs among the pharmaceutical compa-
nies promoting cheaper alternatives reduced their uptake
initially until this was addressed [23].
A number of these concerns led to the discontinuation of
more than 90% of the FDCs marketed in the US in the
1960s and 1970s [5,24]. Following this, the US Food and
Drug Administration (FDA) declared that any new FDC
required proof of benefits versus the single components
before approval, with similar initiatives in Europe [15,24]. In
Europe, the revised regulations from the European Medicines
Agency (EMA) stated that any proposed FDC should be based
on robust and valid therapeutic principles with the potential
advantages assessed in studies against potential disadvan-
tages, and where possible for each dose of the medicines
included in the FDC [5,15,25]. Typically, the medicines in
FDCs should have different mechanisms of action but their
pharmacokinetics and/or pharmacodynamics should not be
appreciably different as this will impact on their effectiveness
in clinical care. In addition, the combination should not be
additive in terms of increased toxicity [1,5,25]. Following these
regulatory changes, we have seen a growth in the number of
FDCs available across countries. For instance, in Europe using
2009 as a baseline, there has been an 8% increase in FDCs
approved by EMA in 2011 and a 15% increase in 2013, with
this trend continuing [5].
Stringent control measures are typically needed to reduce
the availability of irrational FDCs, which has not always been
the case [1,14,26,27]. In India, irrational FDCs were often made
available by state authorities without prior approval of the
Central Drugs Standard Control Organization [28]. However,
these concerns have now been recognized resulting in
a recent ban on 328 FDCs in India [29]. Whilst there have
been concerns with the quality of generic medicines in
Pakistan, there appeared to be no concerns with the bioavail-
ability of for instance rifampicin in FDCs in Pakistan to treat
patients with tuberculosis (TB) [30,31].
1.2. Potential advantages of FDCs
Potential advantages for FDCs compared with prescribing the
components separately or where there are concerns with
monotherapy alone include: (i) improved response rates
where there is an inadequate response to monotherapy
through for instance different mechanisms of action of the
medicines in the combination, (ii) the combination of the
medicines in the FDC achieves the desired effect more rapidly,
(iii) the proposed FDC reduces toxicity with one medicine
potentially counteracting the adverse reactions of another
and (iv) the potential for combining doses that are sub-
therapeutic when used as monotherapy because of issues
such as safety as seen for instance with combination medi-
cines for patients infected with human immunodeficiency
virus (HIV), with these benefits often translating into lower
costs of care [3,15,25,32–36].
FDCs also offer the possibility to simplify administration
where a combination of active substances is already recog-
nized as clinically important. As a result, seeking to improve
adherence as well as targeting multiple disease pathways,
improving efficiency, and potentially saving resources for
patients and the healthcare system [3,7,15,17,37–48].
However, this is not always the case as seen with FDCs for
patients with HIV in France and Spain [49].
FDCs can also help clinicians to effectively manage patient
outcomes from the perspective of long-term care, allowing
them to use combinations of active ingredients that are effec-
tive over time and can improve patient safety as seen for
instance with FDCs for respiratory conditions and pain-
management [23, 50–56]. In addition, potentially reduce
costs and improve the co-operation between physicians and
patients [17,57], with savings enhanced by the availability of
generic FDCs [58]. Co-payment costs can also potentially be
decreased with FDCs versus individual components, which is
particularly important in lower- and middle-income countries
(LMICs) where there are high co-payments [59].
The World Health Organization (WHO) endorses FDCs par-
ticularly for infectious diseases such as HIV, malaria, tubercu-
losis (TB), and Hepatitis B to improve the effectiveness of
treatments especially given the toxicity that can exist with
antiretrovirals as well as help prevent resistance from devel-
oping [15,25,60]. This is particularly important in sub-Saharan
Africa with a high prevalence of both non-communicable
diseases (NCDs) such as hypertension and diabetes along
with infectious diseases including HIV, TB and malaria, and
a high prevalence of patients with joint co-morbidities versus
other continents [15,61–69]. Having said this, a recent
Cochrane review suggested that there was no difference in
outcomes with FDCs versus single-drug formulations com-
bined in managing patients with newly diagnosed pulmonary
TB [70]. However, others have published different findings
(Section 2. 6). In the case of new FDCs for patients with HIV,
the dogma of effective antiretroviral therapy (ART) containing
at least three active substances is being challenged by new
data showing effectiveness with FDCs containing just two
medicines, with costs helped by patent expiry and more
generic formulations becoming available [71]. Treatment
costs can also increase in some settings with the prescribing
of multiple medicines over patented FDCs due to higher rates
of adverse effects [72].
1.3. Aims and objectives
Given the controversies surrounding the use of FDCs, there is
an urgent need to discuss both their advantages and disad-
vantages including their cost-effectiveness. This is particularly
important in LMICs in view of their high prevalence of both
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infectious diseases and NCDs, their considerable resource
pressures, and the continued growth in both morbidity and
mortality from NCDs [73–80]. However, different conclusions
concerning the clinical and economic value of FDCs can be
drawn from the different disease areas as well as within
disease areas depending on the FDCs available within
a country. There is also a perceived paucity of published
data regarding the costs, value, and cost-effectiveness of
FDCs across different disease areas in LMICs versus high-
income countries, which needs to be addressed.
Consequently, the principal focus of the findings and sugges-
tions in this perspective paper is on the costs, value, and
pharmacoeconomics of current and future FDCs aimed
mainly at governments and their advisers in LMICs.
However, patients also play a key role especially in LMICs
where there can be high co-payments and predominant
‘out of pocket’ payments, and patients’ illness can have
a catastrophic effect on the rest of the family [81,82].
An iterative process was used to develop this review paper
building on pertinent publications known to the coauthors in
both infectious diseases and NCDs. These publications were
supplemented by suggested activities from the senior level
coauthors from across countries and continents on potential
ways forward to enhance the prescribing of valued FDCs. This
reflects, as mentioned, the envisaged paucity of published
pharmacoeconomic data on FDCs in LMICs.
We are aware of ongoing initiatives among several LMICs to
strive toward universal health care (UHC) recognizing the
challenges. Besides this, ongoing initiatives across LMICs to
achieve agreed Sustainable Development Goals (SDGs). The
SDGs include a reduction in morbidity and mortality asso-
ciated with NCDs such as cardiovascular and respiratory dis-
eases [74,83–86]. The availability of pertinent and affordable
FDCs can potentially play a key role in achieving these goals
alongside educational and lifestyle changes.
1.4. Methodology
We were aware that there have only been a limited number of
publications assessing the value of FDCs in LMICs, with most
publications typically involving higher-income countries We
are also aware that the potential role and value of FDCs also
vary between and within disease areas and populations as
well as across countries. Consequently, we did not undertake
a formal systematic review; however, based this perspective
paper, including suggested future activities, on pertinent pub-
lications known to the senior level coauthors across multiple
LMICs combined with their extensive experiences with FDCs to
contextualize the findings.
This perspective paper will be divided into three parts to
provide future direction. Firstly, we will briefly review the role
and value of FDCs within and across key infectious and non-
infectious diseases. Infectious diseases include HIV, TB, and
malaria and noninfectious diseases include cardiovascular
diseases (CVD) such as hypertension and type 2 diabetes
mellitus (T2DM) as well as pain management and respiratory
diseases. This also addresses the polypill for patients with CVD
[38,40,87].
The senior-level personnel involved in this paper come
from a wide variety of backgrounds including government
groups, academia, rational use medicine personnel, clinicians,
and patient representative groups. A wide variety of LMICs
have been included in this perspective paper in terms of their
geography, population size, GDP per capita, and progress
toward universal health care. We have used such approaches
before to stimulate debate in priority disease areas to provide
future guidance [88–100]. The 2018 World Bank classification
has been used to categorize countries into LMICs or upper-
income countries [101] wherever pertinent.
We will start with NCDs including CVD, diabetes, respiratory
diseases, and pain management, before discussing the potential
role and value of FDCs in patients with high priority infectious
diseases including HIV, malaria, and TB. These disease areas are
included as they are the subject ofmost publications regarding the
pharmacoeconomics of FDCs across countries and they are the
major source ofmorbidity andmortalitywithin LMICs.Wehavenot
included FDCs for patients with Hepatitis C despite being listed in
theWHO Essential Medicine List (EML) as a result of their consider-
able effectiveness and safety versus previousmedicines since their
prices can be prohibitive for countries and citizens without sub-
stantial discounts. This is exacerbated by pharmaceutical compa-
nies making up to 99.9% gross profit in some countries adding to
the overall cost of medicines [102–106]. Having said this, expendi-
ture on new medicines for patients with Hepatitis C has been
helped by the increasing availability of low-cost generics [107], as
well as treatments provided free or for limited costs in some
countries; however, this is not universal among LMICs [108,109].
Similarly, we have not included topical FDCs for use in dermatol-
ogy althoughwe are aware that there are concerns with a number
of these in LMICs such as India [4,110]. Lastly, we have excluded
combination antibiotics such as amoxicillin with an enzyme inhi-
bitor as thesemedicines should now be reserved under the recent
WHO AWaRe list of antibiotics and there can be considerable
concerns with their availability [11,12,111–114]. We have though
included sulfamethoxazole and trimethoprim FDC to help prevent
Plasmodium falciparum (Pf) malaria and other infections despite
initial concerns that this FDC would impact on the effectiveness of
treatments such as sulfadoxine-pyrimethamine due to shared
mechanisms of action and resistance pattern development [115].
These concerns, however, have notmaterialized and this combina-
tion is now widely used in malaria-endemic countries as prophy-
laxis in both HIV-infected children and adults as well as those
without HIV [116,117].
Secondly, we will document FDC availability within public
health-care systems among a range of LMICs covering multi-
ple countries and continents versus the latest WHO EML. This
is because the WHO EML is recognized as a guide to the
development of national and institutional EMLs with medi-
cines selected for national lists with due regard to disease
prevalence and public health relevance in a country as well
as evidence of clinical efficacy and safety, comparative costs
and cost-effectiveness in a country [111,118,119].
We will also try and explain any variability in the availability
of FDCs between countries as a prelude to lastly discussing
their advantages and disadvantages as well as potential ways
forward to enhance their prescribing where pertinent. These
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deliberations will be based on the perceived value, or lack of it,
of FDCs across the chosen disease areas among the senior level
coauthors. We will also seek to guide key stakeholder groups in
LMICs going forward given the lack of pharmacoeconomic data
to date to make future policy decisions. We will also describe
potential measures to reduce the prescribing of FDCs where
there are concerns. We have undertaken this approach to
address the paucity of published studies addressing the phar-
macoeconomics of FDCs in LMICs versus high-income countries
despite the high prevalence of both infectious and noninfec-
tious diseases in these countries.
2. Role and value of FDCs across disease areas
including health economic evaluations
Wewill start with a review of the role and value of FDCs in patients
with NCDs followed by high priority infectious disease areas
including HIV, malaria, and TB. This will include a consolidation
of studies that have been published in LMICs regarding the phar-
macoeconomics of FDCs in these chosen disease areas.
2.1. Cardiovascular diseases (CVD)
Improved management of CVD is seen as critical with CVD
a leading cause of morbidity and mortality globally as well as
causing a high economic burden to health-care systems
[120,121]. Reducing the morbidity and mortality due to CVD
is particularly relevant in lower-income countries and areas
with under-developed/equipped health-care systems where
rates have increased in recent years exacerbated by changes
in lifestyle, diet, and urbanization [122–128].
Management strategies for CVD and hypertension largely
involve encouraging changes in lifestyle as well as prescribing
medicines from several pharmacological classes.
Consequently, CVD and hypertension may be good candidates
for the development and use of FDCs, with a number of FDCs
currently in use globally.
Overall, FDCs are thought to be a potential solution to the
high pill burden seen in some patients with CVDs, including
those with hypertension, increasing adherence, and the clin-
ical effectiveness of prescribed medicines
[20,35,37,45,57,126,129–139]. A key highlight of the 2018
European Society of Cardiology and European Society of
Hypertension (ESC/ESH) guideline on the treatment of hyper-
tension is the single-pill treatment strategy with the preferred
use of a single pill combination for most patients to improve
their blood pressure (BP) control [135,140]. FDCs also offer the
potential to combine the additive effects of different treat-
ment approaches without having to appreciably increase the
dose of individual medicines, which could increase their side-
effects and potentially decrease adherence in routine care
[37,141,142].
FDCs can also transform the management of patients with
CVD including hypertension by reducing the need for titration
and adding in different classes of medicines to help control
patients’ BP [143]. This is particularly important in LMICs where
the costs of transport and loss of income attending health-
care clinics can adversely affect their attendance and goal
attainment [144,145], with medication follow-up visits among
patients with CVDs already a major issue particularly in Africa
[144–146]. There are ongoing programs across LMICs to
address concerns with adherence to medicines including insti-
gating adherence clubs as well as educational and other pro-
grams for patients given concerns with the educational level
of patients with CVD in a number of LMICs [144,145,147–150].
FDCs can help with this as well as help reduce the potential
for stock-outs by limiting the number of medicines that need
to be available among primary health-care centers [151].
Consequently, FDCs can be viewed positively by all key stake-
holder groups including physicians, pharmacists, and patients
[143,152,153]. Other factors positively influencing the percep-
tion of FDCs include health authority policies toward FDCs and
their costs if these are reduced especially when there are high
co-payments [152]. Their use, however, does vary between
health-care systems for many reasons including clinician/
patient preferences, their costs, and healthcare system
approvals [41,154,155]. There have also been differences in
outcomes between FDCs for CVDs as well as when doses are
missed [156,157].
The renin-angiotensin system (RAS) blockers are seen as
a core component of FDCs for patients with hypertension
except where they are contraindicated [158,159]. Typically,
thiazide diuretics or calcium channel blockers (CCBs) should
be used as first-line treatment especially in sub-Saharan Africa
with RAS blockers – angiotensin-converting enzyme (ACE)
inhibitors or angiotensin receptor blockers (ARBs) – potentially
added in as a single FDC [35,159–161]. However, ACE inhibi-
tors have a more limited effect in reducing blood pressure in
the black population and their prescribing needs to be more
carefully managed in this population [160,162]. Diuretics can
though enhance the effect of RAS blockers whilst minimizing
their undesirable metabolic effects, whilst CCBs and RAS
blockers have synergistic protective effects on the vascular
wall and have been shown to be effective FDCs when com-
bined improving adherence and outcomes [159,163,164]. ACE
inhibitors may also offset one of the major side effects asso-
ciated with CCBs which is pedal edema [165]. In any event, the
management of patients with hypertension is a priority area in
LMICs including sub-Saharan Africa with often patients need-
ing two or more medicines following titration
[144,160,166,167].
Studies assessing the costs and cost-effectiveness of FDCs in
CVD have principally been performed in high-income countries.
These include studies by Sherrill et al. (2011) demonstrating
health-care costs were appreciably lower in the FDC group com-
pared with those patients taking the medicines separately [168].
A study in Canada also showed yearly medicine cost savings with
FDCs [169], and a study in Japan also showed significant medi-
cine cost savings with FDCs versus patients taking multiple
tablets [170]. Other published studies involving high-income
countries have also shown significantly lower costs for FDCs in
CVD versus multiple tablets [45,171–174]. However, Deshmukh
et al. (2017) in the US found the acquisition costs for FDCs were
higher among patients being treated for their hypertension
versus free-pill combinations although the higher costs were
more than offset by lower inpatient costs [43].
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There can though be concerns if FDCs include combination
drugs with similar mechanisms of action such as combining an
ACE inhibitor with an ARB, which increases adverse events and
costs without any obvious additional clinical benefits [175]. In
addition, we have seen some LMICs flooded in recent years with
multiple FDC anti-hypertensive medicines not listed in the WHO
EML and concerns with their rationality [1,36,176]. Having said
this, combinations of anti-hypertensive medicines are typically
needed in LMICs, especially in sub-Saharan Africa, given the high
prevalence of hypertension as well as resistant hypertension that
can exist in these countries [144,149,160,167,177]. However, the
nature of the anti-hypertensive medicines in the various combi-
nations can be important especially given, as mentioned, con-
cerns with ACE inhibitors and ARBs among the black population
[160,162]. A recent meta-analysis showed that lowering BP by
10 mmHg resulted in a 20% reduction in the risk of major
cardiovascular events. However, despite various
anti-hypertensive classes reducing specific clinical outcomes,
i.e. diuretics appearing more effective for heart failure and CCBs
more effective for stroke prevention with beta-blockers and ACE-
inhibitors not ideal, overall all classes of anti-hypertensives had
similar effects in reducing major cardiovascular disease [178].
Currently, four groups of anti-hypertensive FDCs are listed in
the WHO EML (21st Edition 2019). These include an ACE inhibitor
plus a CCB, ACE inhibitor plus a thiazide or thiazide-like diuretic,
ARB plus a CCB and an ARB plus a thiazide or thiazide-like diuretic
[111]. However, since lisinopril is preferred over other ACE inhibi-
tors, telmisartan over other ARBs, amlodipine versus other once-
daily CCBs, and hydrochlorothiazide (HCTZ) over other similar
diuretics, the current 21st WHO EML lists lisinopril plus amlodipine,
lisinopril plus hydrochlorothiazide, telmisartan plus amlodipine
and telmisartan plus hydrochlorothiazide [111]. This is in line
with treatment guidance that recommends initiation with at
least two anti-hypertensive medicines for those patients with
markedly elevated blood pressure, and follows prior concerns
about the limited availability of FDCs in the WHO EML [179–181].
There have also been combinations of statins and
anti-hypertensives to help reduce CV events including
FDCs of amlodipine and atorvastatin. However, there
have been mixed findings regarding their effectiveness
including increased adherence as well as costs versus sin-
gle tablets combined [17,139,182–185]. Currently, no FDC
containing a statin and an anti-hypertensive is listed in the
WHO EML [111].
Besides this, there have also been FDCs containing different
lipid-lowering medicines including ezetimibe combined with
either simvastatin, atorvastatin, or rosuvastatin [186–190]. The
belief is that by combining different lipid-lowering medicines
with different mechanisms of action adherence can be
enhanced along with improved effectiveness and outcomes
[191]. However, there have been concerns among health
authorities regarding the effectiveness of ezetimibe in redu-
cing CV events in reality, which has limited its use in practice
[192,193]. Currently, no FDCs containing combinations of dif-
ferent lipid-lowering treatments with different mechanisms of
action are listed in the WHO EML, potentially reflecting some
of the controversies seen [111].
There are also FDCs containing lipid-lowering medicines and
oral antihyperglycemic agents (AHAs) to try and improve
outcomes in patients with both dyslipidemia and T2DM through
reducing the pill burden [194]. However, currently, no FDCs
containing a statin and AHA are listed in the WHO EML [111].
Attention in recent years has turned to the development and
availability of a ‘polypill’, which is an oral tablet containing low
dose aspirin, a statin, and at least one anti-hypertensive medicine
to prevent CV events [195]. Such a pill is potentially seen as an
affordable and cost-effective for the prevention of CVD especially
in LMICs if the polypill wasmade available based on current public
sector prices [38,40,42,143,196–199]. Polypills have also been
shown to enhance adherence, are well tolerated and reduce risk
factors in both primary and secondary prevention [87,196,200–
202]. However, there are concerns that a single polypill may not be
suitable for all patients and it could well be necessary to develop
several different types of polypills tomeet the needs of all patients
tomaximize effectiveness and efficiency [203,204]. In addition, the
availability of FDCs has to be balanced against the increased risk of
duplication of medicines among hypertensive patients being pre-
scribed FDCs and concerns with prescribing a polypill initially
without titration [87,205].
2.2. Type 2 diabetes mellitus (T2DM)
First-line treatment in patients with T2DM is typically metfor-
min [46,206–209], with the subsequent initiation of additional
oral antihyperglycemic agents (AHAs) if patients fail to achieve
target HbA1c levels. FDCs have been developed to reduce the
pill burden as well as potentially enhance adherence and
outcomes in patients with T2DM [46,210–212], with reduced
pill burden along with improved effectiveness and reduced
side-effects welcomed by patients [213]. Poor control of
patients with T2DM is a concern especially among African
countries [162,214–217].
FDCs include those with a sulfonyl urea (SU) and metformin,
metformin and acarbose, DPP-4 (dipeptidyl peptidase-4) inhibi-
tors and metformin, thiazolidinedione and metformin, alogliptin
and pioglitazone, sodium-glucose transport protein 2 (SGLT2)
inhibitors and metformin, and a SGLT2 inhibitor and dipeptidyl
peptidase-4 (DPP-4) inhibitor [210,218–220]. FDCs containing
metformin and a DPP-4 inhibitor, as well as metformin and
SGLT2 inhibitors are seen in particular as providing metformin
with complementary mechanisms of action to improve glycemic
control whilst reducing the pill burden, and similarly with sax-
agliptin/dapagliflozin FDCs [218,221–224].
In their systematic review principally involving high-income
countries, Vijayakumar et al. (2017) found improved adherence
with FDCs leading to improved effectiveness [225]. However, it
was difficult to determine the actual level of clinical significance
with no studies appearing to randomize patients to either the
FDC or the separate components [225]. Lokhandwala et al.
(2016) suggested that improved adherence and compliance
with FDCs may well translate into reduced health-care utiliza-
tion and costs in the US [226]. However, there are issues of
affordability in LMICs, especially with the newer oral anti-
diabetic medicines.
There are also concerns with both published and unpublished
clinical trial data of five metformin containing FDCs in India which
currently account for 80% of all metformin sales [27]. Concerns
include the limited number of patients in the clinical trials, which
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typically were not conducted in India, and whether improved
health gain is seen for the FDC versus co-prescribing the individual
components together. Evans et al. (2015)were also concernedwith
the typical length of follow-up in clinical trials with for instance one
study involving only 40 patients followed up for just 2 weeks [27].
In their critique of Evans et al. though, Kannan et al. (2015) stated
that SU/metformin FDCs are particularly popular among general
practitioners and patients in India as they contain lower doses of
metformin to reduce or stop gastrointestinal side-effects as well as
result in a rapid decrease in blood glucose concentrations.
However, the relatively high doses of SUs used in the FDCs
increases bodyweight worsening insulin resistance and reversing
the beneficial CV effects when metformin is prescribed first line in
higher doses [59]. In view of this, Kannan et al. recommended
using each medicine separately and titrating doses accordingly
[59]. This though can be a challenge in India with current high
patient co-payments as the cost of the FDCs can often be cheaper
than the combined costs of the separate tablets [59].
The disadvantages of FDCs can include difficulties with
determining the cause of poor effectiveness and/or the side
effects of treatment, patients’ refusal to accept their disease if
FDCs are prescribed as initial treatment instead of for instance
metformin, and potentially higher costs [227].
Currently, no FDC for patients with T2DM is currently listed
in the WHO EML [111], and there are issues with the afford-
ability of most of these FDCs in LMICs.
2.3. Respiratory diseases
In patients with asthma, treatment strategies using combina-
tion inhalers of corticosteroids (ICS) and long-acting β agonists
(LABAs) are seen as the most effective and safe approach to
prevent exacerbations [228–231]. For instance, Tohda et al.
(2010) demonstrated that the FDC of fluticasone and salme-
terol resulted in a higher proportion of totally controlled
weeks per patient with asthma versus fluticasone [232]. This
builds on guidelines advocating the use of such combinations
[231,233]. This was based on the evidence that LABAs can
potentially increase the risk of mortality if used in patients
with unstable asthma without the concomitant use of ICS
therapy [233,234].
Published studies have also compared the effectiveness of ICS
(fluticasone) and LABA (salmeterol) FDCs with other inhaled ICS
containing regimens including LABAs in patients with chronic
asthma. In the UK, Doull et al. (2007) ascertained that in adults,
this FDC was cheaper than increasing the dose of fluticasone,
and in children, the FDC was similarly effective compared with
fluticasone plus salmeterol in separate inhalers; however, its use
resulted in annual cost savings of between GB£47 and GB£77 per
child based on UK costs [235]. Studies in Canada have investi-
gated the cost/QALY of the fluticasone/salmeterol FDC [236], and
in Japan, Tohda et al. (2010) demonstrated that the FDC of
fluticasone and salmeterol resulted in lower mean direct man-
agement costs [232]. Previously, Jonsson et al. (2004) in Sweden
had demonstrated that a budesonide (ICS) and formoterol
(LABA) FDC had improved effectiveness and lowered costs versus
separate inhalers [237]. These though are all studies from high-
income countries.
Currently, only one ICS/LABA combination (budesonide and
formoterol) is included in the WHO EML [111]. This reflects the
fact that the listed medicines within the WHO EML should be
the example of the class for which there is the best evidence
for effectiveness and safety. In some cases, this may be the
first medicine that is licensed for marketing with no overall
difference in terms of efficacy and safety data between the
various FDCs available. In addition, the listed medicine or FDC
is generally available at the lowest price based on interna-
tional drug price information sources [111].
LABA/ICS FDC inhalers have also been used in patients with
chronic obstructive pulmonary disease (COPD) with studies
assessing their effectiveness as well as their cost-effectiveness
across countries including LMICs [238–244]. However, recently
there are concerns with an increased risk of serious pneumonia
with LABA/ICS FDCs resulting in guidance that they should only
principally be given to COPD patients with asthma-like symp-
toms [23,245,246]. However, this combination is still being pre-
scribed despite concerns [247].
The costs of LABA/ICS FDC inhalers have started to come
down among high-income countries with an increasing use of
lower-cost FDCs combined with initiatives to reduce the ster-
oid burden and improved monitoring of patients [23,231,248].
This should further enhance their cost-effectiveness as well as
their access among LMICs.
We have not included any evaluation of FDC inhalers con-
taining an ICS plus a short-acting β agonist (SABA), with ICS
typically recommended as first line treatment for patients with
asthma before moving onto an ICS/ LABA FDC for mainte-
nance therapy [231]. As a result, limited use of ICS/ SABA
combinations across countries and also discontinuations [23].
LABA/long-acting antimuscarinic agent (LAMA) FDC inha-
lers also appear beneficial with enhancing bronchodilation in
patients with COPD uncontrolled on single agents [50,249–
254]. This builds on GOLD guidance which recommends that
when a single bronchodilator fails to achieve the desired out-
come a second bronchodilator from a different class may be
added [249]. There have also been studies assessing the costs
and cost-effectiveness of LABA/LAMA FDCs typically in high-
income countries [249,255–257]. However, currently, LAMAs
are unaffordable in a number of LMICs including the public
health-care system in South Africa. It is hoped that as more
formulations are launched, costs will come down to more
affordable levels to enhance access.
It is recognized that pharmacists and other professionals
can assist in lowering the costs of medicines to treat patients
with COPD through education and improved adherence
[258,259]. These activities, coupled with lower costs of inhaler
FDCs as different combinations are launched competing with
others, should further enhance their use and improve patient
care in a cost-efficient manner.
2.4. Pain
Combinations of medicines may often be needed for pain man-
agement, especially severe pain, with often a ‘multimechanistic’
approach needed [53]. As a result, a combination of analgesics or
an FDC containing analgesics with different mechanisms of action
may be needed to increase the effectiveness and/or reduce the
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side effects versus increasing the doses of single agents alone [53].
This is seen with the FDC of acetaminophen/ibuprofen in patients
with moderate to severe postoperative dental pain where the
combination provided greater and more rapid analgesia than
comparable doses of either agent alone [56]. Besides this, FDCs
of tramadol and paracetamol may be opioid sparing without
sacrificing effectiveness, which is seen as important given some
of the recent concerns with tramadol especially its potential for
abuse [260–263]. In addition, a tramadol/paracetamol FDC can
present a potential alternative to nonsteroidal anti–inflammatory
drugs (NSAIDs) in the elderly reducing concerns with possible
gastrointestinal side-effects [264].
In their study, Cristancho et al. (2013) found that an FDC of
acetaminophen and codeine (AC) had lower cost and was more
effective in reducing pain within the first hours after administra-
tion versus an acetaminophen and hydrocodone (AH) FDC or an
acetaminophen plus tramadol (AT) FDC [265]. The costs/num-
bers needed to treat for each formulationwere $1816 Colombian
pesos/2.2 for AC, $4772 Colombian peso/2.3 for AH, and $5342/
2.6 for AT. Using AC as the comparator, the ICER for AT from
a payer’s perspective was $8790 Colombian pesos and $29,640
Colombian pesos for AH [265].
FDCs of paracetamol and NSAIDs may also offer superior
analgesia effects compared with either medicine alone [55].
This is important especially in the elderly resulting in calls to
develop an FDC of NSAIDs combined with a gastroprotective
medicine such as a proton pump inhibitor or a high-dose
histamine-2 receptor antagonist [266].
There are concerns though regarding FDCs for management
of pain. Many of these medicines are misused or dangerous in
overdose and currently no FDC for pain management is included
in the WHO EML [111]. In addition, there are concerns that the
general principles of pain management may be compromised by
high use of FDCs including adhering to the general principles for
the management of chronic pain [267].
2.5. Malaria including prevention
Both dihydroartemisinin-piperaquine (DP) and sulphadoxine-
pyrimethamine (SP) have been used for malaria prevention in
pregnant mothers, with a recent review suggesting that inter-
mittent preventive treatment may reduce maternal and pla-
cental malaria and that monthly DP appears more effective
than SP in reducing placental malaria [268].
There are also ongoing initiatives with DP combinations to
improve their packaging to facilitate correct use to further
improve their overall effectiveness and value, with published
studies showing a single course treatment for uncomplicated
falciparum malaria is well tolerated [269,270]. Assi et al. (2017)
have also demonstrated that the artesunate–amodiaquine FDC is
well tolerated to treat uncomplicated PCP malaria under real-life
conditions [271], with this combination now widely used. Banek
et al. (2018) have shown that co-formulated artemether–lume-
fantrine (AL) and fixed dose amodiaquine–artesunate (AQAS)
have high self-reported adherence rates among children [272].
Overall, ALwas less likely to be taken correctly at one of the study
sites; however, it was better tolerated overall than AQAS which
may enhance its overall utility in routine clinical care [272]. Itoh
et al. (2018) found the artemether-lumefantrine FDC effective in
treating uncomplicated P. falciparum malaria among Brazilian
patients in the Amazon jungle, strongly supporting the contin-
ued use of this FDC as a first-line therapy [273]. Recently Ebenebe
et al. (2018) compared the effectiveness of 3-day regimens of AL,
artesunate-amodiaquine (AA), and DP among 910 under-five
children in Nigeria. The authors found all three evaluated treat-
ments were effective in the management of uncomplicated
malaria in young children; however, DP appeared slightly more
efficacious than either AL or AA [274].
Studies are also ongoing to increase the dose of DP and extend
the dosing schedule to four monthly doses to reduce the inci-
dence of malaria especially during the high transmission season,
and this may well continue to enhance the value of this FDC [275].
Artemisinin-based combinations or chloroquine in combina-
tion with a short course of primaquine have also been shown to
be highly effective in the treatment of vivax malaria in Brazil
[276]. An FDC of mefloquine combined with artesunate has also
been studied in cases of falciparum malaria in the Brazilian
Amazon basin and shown to have acceptable efficacy, safety,
and tolerability [277]. However, artesunate–mefloquine FDCs
have been used infrequently in Africa due to a perceived poor
tolerance to mefloquine although recent studies in children in
Africa are now suggesting otherwise [278].
There are concerns though with the number and availability
of unapproved FDCs to treat malaria among LMICs with recent
estimates suggesting almost half of the sales value and volume
of antimalarials are generated by unapproved products [279].
This calls for tighter regulatory process to avoid patient harm as
well as appropriate training of pharmacists and their assistants
when treatments are dispensed without a prescription [62].
There are also concerns about the pharmacokinetic profile of
some FDCs for malaria, which again requires further attention
going forward.
Overall though, FDCs are routinely used to prevent and
manage patients with malaria due to their effectiveness and
tolerability, and this will remain. This is endorsed by the WHO,
with six FDCs for malaria and its prevention currently included
in the WHO EML [111]. However, there is a paucity of informa-
tion regarding the costs of treating patients with malaria as
well as the cost-effectiveness of FDCs. Ezenduka et al. in 2017
estimated the costs of treating uncomplicated malaria at
a public health-care facility in Nigeria [280]. A recent study in
Tanzania suggests that AL and DP as the first- and second-line
treatment, respectively, for patients with malaria will save
approximately US$64,423 per year whilst achieving a 3%
reduction in the number of malaria cases compared with AL
plus quinine [281]. However, a policy that uses DP as the first-
line anti-malarial medicine will consume an additional
US$780,180 per year whilst achieving a further 5% reduction
in the number of malaria cases versus AL followed by DP [281].
Key areas of pharmacoeconomic research in the future will
also center around funding monthly prophylaxis versus focused
screening and treatment of identified cases [282]. In addition,
assessing the simultaneous use of artemether-lumefantrine, arte-
sunate-amodiaquine, and dihydroartemisinin-piperaquine FDCs
against strategies in which these treatments would be cycled or
used sequentially [283].
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2.6. Tuberculosis (TB)
The treatment regimen for TB can be problematic with patients
required to take four medicines during the two-month intensive
phase followed by a continuation phase of 4 months with two
medicines adversely affecting patient adherence in practice
[284–286]. These concerns have resulted in the development of
FDCs to enhance adherence rates and reduce default rates. In
a study from Brazil by Braga et al. (2015), FDCs containing
rifampin (R), isoniazid (H), and pyrazinamide (Z) combined with
ethambutol (E) reduced default rates and halted the potential
increase in resistance rates compared with an FDC of
RH plus pyrazinamide separately [287]. However,
a previous meta-analysis published in 2013 failed to show any
difference in the acquisition of drug resistance, bacterial conver-
sion rates after 2 months of treatment, or the incidence of
adverse drug reactions between patients on FDCs versus admin-
istering the medicines separately [288]. Gallardo et al. (2016)
came to similar conclusions in their Cochrane review [70]. Lima
et al. (2017) also found that four-medicine FDCs did not improve
culture conversion after 2 and 6 months of treatment versus the
separate medicines; however, the FDCs provided greater patient
comfort by reducing the pill burden as well as reducing gastro-
intestinal adverse effects [289].
In Brazil, the FDC containing rifampicin, isoniazid, pyrazina-
mide, and ethambutol (HRZE) has been available since 2009
produced by local laboratories through a Partnership for
Productive Development Agreement [290]. In spite of the meth-
odological limitations casting doubt on the findings [291], an
interrupted time series evaluating patient outcomes with this
FDC found no difference in treatment abandonment rates
although there was a trend toward decreased cure rates [292].
Overall, FDCs can simplify treatment regimens, which may
be important in some patients, along with instigating thera-
peutic drug monitoring (TDM) in selected patients to help
detect non-adherence early as well as help manage potential
drug:drug interactions [293]. Having said this, TDM is likely to
be unavailable or unaffordable in most LMICs. Strategies to
further enhance adherence rates include opening more treat-
ment centers as well as community outreach centers in rural
areas where access is a concern [294]. This builds on strategies
to provide standardized anti-TB drug regimens free of charge
to all patients administered under direct observation to
improve patient outcomes combined with other measures
such as patient support [63,295]. We are also seeing in South
Africa standard operating procedures instigating enhanced
adherence counseling in patients with continued positive
smear tests [296,297], and this is continuing.
There can though be concerns with FDCs for patients with TB.
These include concerns with poor bioavailability with some FDCs
including those with rifampicin as well as concerns when some
patients are switched between different rifampicin formulations
without adequate monitoring. In addition, concerns with
enzyme level elevations, increases in adverse drug reactions
with some combinations, concerns with adverse drug reactions
with certain FDCs for patients with both HIV and TB, as well as
issues associatedwith TDM and dose adjustments especially with
rifampicin [18,298]. Having said this, the WHO currently endorses
five FDCs for the treatment of TB in its EML [111].
2.7. Human immunodeficiency virus (HIV)
FDCs are also increasingly used in patients with HIV to reduce
the pill burden, with studies showing a lower pill burden with
FDCs appreciably enhances adherence rates. This is helped by
greater patient preference for FDCs as well as improved out-
comes including greater viral suppression and improved
health-related quality of life (HRQoL) [44,299–309]. However,
there is a large variability in the individual components of
FDCs used to treat patients with HIV, which can confound
the associations reported. As a result, the increase in adher-
ence due to FDCs is not consistently transposed to improving
patient outcomes with mixed results reported for viral sup-
pression rates [310] and health-related quality of life (HRQoL)
[311]. Key aspects associated with lower HRQoL included
being single, smoking, and having co-morbid disease [311].
The WHO endorses the use of FDCs containing tenofovir/
lamivudine/dolutegravir (TLD) due to their improved tolerability
and effectiveness, a reduced risk of resistance acquisition, lower
discontinuation rates, and fewer drug interactions [312,313].
Meireles et al. (2019) in Brazil also found that a TLD combination
of TDF/3TC (tenofovir/lamivudine) combined separately with
dolutegravir (DTG) was more effective in suppressing viral load
than a tenofovir/lamivudine/efavirenz (TLE) FDC, which was not
driven by higher adherence rates [314]. As a result, Phillips et al.
(2018) modeled that DTG containing combinations is predicted
to be both effective and cost-effective among sub-Saharan
African countries [315]. Zheng et al. (2018) also found that
a generic DTG-based regimen is likely to be cost-effective in
India; consequently, they believed this regimen should be
recommended as initial therapy in patients newly diagnosed
with HIV in India [316]. Having said this, there are still concerns
regarding DTG and its combinations among LMICs. These
include the need for further studies to better determine the risk
of adverse birth outcomes when DTG is initiated pre-conception
as well as assessing its effectiveness when co-administered with
treatments for patients with TB [317]. However, there are
ongoing studies assessing the optimal dosing regimen of DTG
with rifampicin as well as its safety in pregnant women helping
to address these concerns [313,318–320]. The interactions
between efavirenz and bedaquiline are a problem for patients
with HIV who have M/XDR-TB and who are taking bedaquiline
containing FDCs. These patients need to be switched from
a generic efavirenz-containing FDC regimen to twice-daily nevir-
apine with separate companion pills to address concerns [321].
These patients also need to be closely monitored following
switching to other antiretroviral (ART) FDCs as there can subse-
quently be low ART adherence in these patients [321]. Patient
monitoring should happen generally when patients are switched
between ARTs.
Studies typically undertaken in high-income countries have
shown that FDCs prescribed first-line are generally seen as more
effective and less costly than other regimes [302,308,322–324].
Cohen et al. (2013) in the US found lower pharmacy costs, fewer
hospitalizations, and lower hospital costs in patients prescribed
FDCs, which resulted in significantly lower overall total health-care
costs [32], with a study in Spain suggesting overall costs will
increase with multiple tablet regimens versus FDCs due to
a greater prevalence of adverse drug events [72]. Colombo et al.
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(2014) in Italy also found lower costs for FDCs [33]. However,
Angeletti et al. (2014) in Italy found only a 1.5% reduction in
average annual costs with FDCs versus multiple drug regimens
[325]. Contrasting this, Libre et al. (2018) demonstrated greater
efficiency for multiple tablets combined in patients with HIV in
France and Spain versus FDCs, which was mainly due to similar
effectiveness but lower direct costs with multiple tablets [49].
These differences may be sensitive to the availability of generic
formulations [49,58].
Among LMICs, in Brazil, a cost analysis per responder was
performed alongside a cohort study (J Costa unpublished data)
and the authors found the mean annual cost per patient initiated
on an FDC was lower than for those prescribed multiple tablet
regimens [301]. This was mainly due to lower costs of ART and
lower switching rates. There was though no difference in effec-
tiveness rates between groups after 12 months of treatment
although overall a better cost-effectiveness ratio for the FDC [326].
Overall, FDCs for patients with HIV are well accepted and
endorsed in the WHO EML [111]. Careful consideration is
needed when the manufacturers of the different components
of FDCs lower their unit costs potentially affecting overall
prices and cost-effectiveness of FDCs versus multiple tablet
regimens. Sweet et al. (2016) found that overall costs
increased in the US with patented FDCs versus generic multi-
ple drug regimens despite lower in-patient costs due to acqui-
sition cost differences [327].
There are also calls to develop a cotrimoxazole and isonia-
zid FDC together with pyridoxine to help prevent TB from
developing in patients with HIV as a cost-effective
option [328].
2.8. Infectious diseases treated with antibiotics
We have not included combination antibiotics such as amox-
icillin combined with an enzyme inhibitor in this paper as
these medicines should be reserved under the recent WHO
AWaRe list of antibiotics and there can be considerable con-
cerns with their availability and use [11,12,111–114].
Consequently, the prescribing and dispensing of these FDCs
should not be encouraged but restricted.
2.9. Consolidated pharmacoeconomic findings in LMICs
Table 1 contains details of published studies regarding the
cost-effectiveness of FDCs among LMICs contained in
Sections 2.1 to 2.8. Typically, there are considerably more
published studies regarding FDCs for NCDs among higher-
income countries versus LMICs.
In view of the comparative lack of pharmacoeconomic
studies regarding FDCs in LMICs coupled with ongoing con-
cerns, there is a need to consider both the positive points and
concerns regarding FDCs among senior-level personnel in
a range of LMICs to provide guidance regarding their future
role and value as well as potential ways forward.
2.10. FDC availability across LMICs by disease area
Table 2 contains details of FDCs available in the public sector,
which means full or partial reimbursement from public
sources, across a wide range of LMICs. This includes FDCs
within the WHO EML as well as other FDCs within the country.
Typically, where there are both private and public markets in
a country, there is greater availability of FDCs in the private
market, e.g. Brazil, South Africa, and Sudan, with typically no
reference to the WHO EML. The exception can be for medi-
cines for malaria, TB and HIV where in some countries these
are dispensed free of charge in the public sector with the help
of the Global Fund, e.g. Sudan.
The differences in the availability of different FDCs within
and between the different countries reflect differences in the
prevalence of infectious diseases between countries especially
for malaria and TB. In addition, the priority for respiratory dis-
eases versus CV disease, the potential wealth of the country
especially regarding the number of FDCs for CV diseases, as well
as the extent of regulatory control. For instance, we have not
included India in Table 2 in view of the appreciable number of
FDCs still available in the country, which are often irrational,
although this is starting to change [1,14,27–29,36]. Concerns
with the prescribing of FDCs in India was emphasized in the
study by Balat et al. (2014) where only 5.8%, 9.8%, and 10.9%
FDCs prescribed by physicians in Ahmedabad city were
included in the WHO EML (2010), National (2011), and Gujarat
State (2011) EML, respectively, [330]. Overall in India, there have
been 98 different FDCs for CV diseases including hypertension,
26 FDCs for T2DM, 12 inhaler FDCs for patients with respiratory
diseases including formoterol and budesonide, and 24 FDCs for
the management of pain. There have also been 9 FDCs for
malaria including 5 on the WHO EML, 5 FDCs for malaria includ-
ing 2 on theWHO EML and 18 FDCs for HIV including one on the
WHO EML (Table 2). As a result, there is an urgent need to
sensitize physicians and undergraduates to potential concerns
with the irrational prescribing of FDCs where pertinent (Box 2)
[331]. This is beginning to happen in India with, as mentioned,
a significant reduction in the number of FDCs available (328 in
all) in recent years [29].
2.11. Positive and negative issues with FDCs across
disease areas
Table 3 contains general positive clinical and economic
considerations associated with FDCs that enhance their pharma-
coeconomic profile, which is based on the perspectives and
experiences of the senior level coauthors from multiple LMICs.
Table 4 contains details of additional benefits for the different
infectious and noninfectious disease areas where FDCs are typi-
cally prescribed.
Tables 5 and 6 contain concerns that the senior level
coauthors have regarding FDCs, which are both general and
disease specific.
Box 1 contains suggestions for possible activities that can
be undertaken within countries to enhance the prescribing of
valued FDCs given the concerns that have existed regarding
FDCs with appreciable variability in their availability among
LMICs (Table 2). Potential activities include a greater role for
patients and patient organizations to enhance the prescribing
and adherence to valued FDCs to enable patients to attain and
retain treatment goals especially those with chronic NCDs
[332]. In addition, helping to ensure FDCs are produced at
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low costs, which is especially important where there are issues
of access and high co-payments, combined with incentives to
enhance their development and availability [333]. Finally,
there is a great need for more published studies and health
technology assessments demonstrating their value in LMICs
given the current paucity of studies to date (Table 1).
Box 2 documents potential activities that can be under-
taken to reduce or negate the availability and prescribing of
FDCs of limited value and/or where there are concerns with
their irrationality.
2.12. Limitations
We are aware of a number of limitations to this paper.
These include the fact that we did not undertake
a systematic review for the reasons stated. As a result,
there may be some biases in our findings. However, we
tried to negate this through using senior-level academic
and health authority personnel from across an appreciable
number of LMICs to give guidance on potential publica-
tions regarding FDCs across multiple disease areas to
Table 1. Published pharmacoeconomic studies of FDCs in LMICs.
Author, year and country FDCs and methods Principal findings
Non Communicable Diseases
Cardiovascular disease
Gaziano et al (2006) –
multiple countries [329]
● 2 FDCs – one containing aspirin, lovastatin lisinopril, and
amlodipine (forerunner to the polypill) for primary prevention
and a similar FDC for secondary prevention with metoprolol
replacing amlodipine among six regions involving LMICs
● Costings based on the International Drug Price Indicator
Guide
● Preventive strategies could result in a 2-year gain in life
expectancy
● ICERs for secondary prevention ranged from 306 USD/QALY to
388 USD/QALY gained.
Sing et al (2018) – India [38] ● Polypill for secondary prevention in India versus usual care
groups
● The price of the polypill was constructed using a range of
scenarios: $0.06 to $0.94/day.
● The mean cost per patient was significantly lower with the
polypill strategy at -203 USD per person (95% CI: −286,
−119, p < 0.01)
● ICERs ranged from a cost-saving to $75 per 10% increase in
adherence for the polypill priced at $0.94/day
Lin et al (2019) – multiple
countries [40]
● Polypill containing aspirin, lisinopril, atenolol, and simvastatin
● Microsimulation models used to assess its cost-effectiveness
for secondary prevention versus current care in China, India,
Mexico, Nigeria, and South Africa
● Variety of sources used for prices including retail market
prices
● At public-sector prices, the ICER was Int168 USD per DALY
averted in China, Int$154 in India, Int$88 in Mexico, Int$364
in Nigeria, and Int$64 in South Africa, amounting to
0·4–6·2%/capita GDP in these countries
● The ICER increased to 3·3–14·6%/capita GDP at retail market
prices
T2DM None identified
Respiratory Diseases – Altaf
et al (2015) – India [242]
● Prospective observational study undertaken to evaluate the
clinical and economic consequences of salmeterol/fluticasone
(SF) – Group I, formoterol/budesonide (FB) – Group II, and
formoterol/fluticasone (FF) – Group III – in severe and very
severe chronic obstructive pulmonary disease patients
● 90 COPD patients were divided into three groups
[NB – No longer recommended [23,245,246]].
● The 3% and 2% increase in FEV1 in Groups I and II,
respectively, was highly significant vs. 0.2% increase in
Group III
● The mean total costs over 6 months was Rs. 29,725/- for
Group I, Rs. 32,602/- for Group II, and Rs. 37,155/- for Group III
● The incremental cost-effectiveness of FB versus SF was Rs.
37,781/- per avoided exacerbation and Rs. 661/-per symptom-
free day
Pain management –
Cristancho et al (2013) –
Colombia [265]
● The cost-effectiveness of three different FDCs indicated for
moderate and severe acute pain – acetaminophen 500 mg +
codeine 30 mg (AC), acetaminophen 500 mg + hydrocodone
5 mg (AH) and acetaminophen 325 mg + tramadol 37.5 mg
(AT)
● Prices typically Institutional prices
● The prices/numbers needed to treat were $1816Colombian
pesos/2.2 for AC, $4772 Colombian peso/2.3 for AH and
$5342/2.6 for AT
● Using AC as the comparator, the ICER for AT from a payer’s
perspective was $8790 Colombian pesos and $29,460
Colombian pesos for AH
Infectious diseases
Malaria
Mori et al (2016) – Tanzania
[281]
● Dynamic Markov decision model developed
● Model based on clinical and epidemiological estimates to
predict the budget impact of DP as either first- or second-line
treatment alongside AL
● Prescribing AL and DP as first- and second-line treatment,
respectively, will save approximately $64,423/year whilst
achieving a 3% reduction in the number of malaria cases
versus AL + quinine
● Prescribing DP as first line will add $780,180/year but achieve
a further 5% reduction in the number of malaria cases vs. AL
followed by DP
TB None identified
HIV
Zheng et al (2018) -
India [316]
● 1 FDC (EFZ/TDF/3TC) vs. TLD (DTG + TDF/3TC)
● Microssimulation model
DTG + TDF/3TC is cost-effective with an ICER = 130 US$/life
year saved
Costa (2019) – Brazil [326] ● 1 FDC (EFZ/TDF/3TC) vs. multiple tablet regimens with the
same formulation of the FDC and other multiple tablet
regimens
● Cost per responder at 52 weeks
● Adjusted for loss to follow-up
FDC was cost-effective with an ICER of US$19583 for multiple
tablet regimens with the same composition of the FDC and
US$41,128 for other multiple tablet formulations
ACE, angiotensin-converting enzyme; AL, artemether–lumefantrine; DALY, disability-adjusted life-year; DP, dihydroartemisinin-piperaquine; DTG, dolutegravir;
EFZ, Efavirenz; FDC, Fixed dose combinations; ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life year; TDF, tenofovir disoproxil fumarate;
3TC, lamivudine.
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Table 2. Availability of FDCs among the various LMICs (Public sector only and only oral medicines apart from inhalers).
Albania Botswana Brazil Bulgaria Cameroon Estonia Ghana
Infectious diseases
Antibiotics (Prevention malaria, etc)
sulfamethoxazole + trimethoprim Yes Yes Yes Yes Yes Yes Yes
HIV FDCs
abacavir + lamivudine No Yes No Yes Yes Yes Yes
dolutegravir + lamivudine +
tenofovir
Yes Yes No No No No No
efavirenz + emtricitabine +
tenofovir
No Yes No No Yes No Yes
efavirenz + lamivudine + tenofovir No Yes Yes No Yes No Yes
emtricitabine + tenofovir No Yes Yes Yes Yes Yes Yes
lamivudine + nevirapine +
zidovudine
No Yes No No Yes No Yes
lamivudine + zidovudine No Yes Yes Yes Yes Yes Yes
6 other FDCs
available
3 other FDCs 2 other
FDCs
available
5 other INNs
of FDCs are
4 other FDCs 4 other
FDCs
Anti TB Medicines
isoniazid + pyridoxine +
sulfamethoxazole +
trimethoprim
No No No No Yes No No
ethambutol + isoniazid +
pyrazinamide + rifampicin
No Yes Yes No Yes No Yes
ethambutol + isoniazid +
rifampicin
No Yes No No Yes No Yes
isoniazid + pyrazinamide +
rifampicin
No Yes Yes No Yes No Yes
isoniazid + rifampicin No Yes Yes No Yes Yes Yes
Antimalarial medicines including prevention
artemether + lumefantrine No Yes Yes No Yes No Yes
artesunate + amodiaquine No Yes No No Yes No Yes
artesunate + mefloquine No No Yes No No No No
artesunate + pyronaridine
tetraphosphate
No No No No No No No
dihydroartemisinin + piperaquine
phosphate
No No No No Yes No Yes
sulfadoxine + pyrimethamine No Yes No No Yes No Yes
Non-communicable diseases
Cardiovascular – Hypertension, etc
lisinopril + amlodipine No No No Yes No Yes No
lisinopril + hydrochlorothiazide No Yes No Yes No No No
telmisartan + amlodipine No Yes No Yes No Yes No
telmisartan + hydrochlorothiazide Yes Yes No Yes No No No
12 other FDCs 24 INNs of
FDCs are available
26 other
FDCs
2 other
FDCs
Diabetes
None No 1 FDC
available
No 10 INNs of
FDCs are available
9 FDCs
available
No
Respiratory
budesonide + formoterol Yes Yes Yes Yes No Yes Yes
Other FDCs also
reimbursed
1 other FDC 10 other FDCs are
available
10 other
FDCs
1 other
FDC
Pain
None No 1 FDC
available
No No 5 other
FDCs
available
No No
Iran Kenya Kosovo Latvia Nigeria Romania
Infectious diseases
Antibiotics (Prevention malaria, etc)
sulfamethoxazole + trimethoprim Yes Yes Yes Yes Yes Yes
HIV FDCs
abacavir + lamivudine No Yes Yes Yes No Yes
dolutegravir + lamivudine + tenofovir No Yes No No No No
efavirenz + emtricitabine + tenofovir Yes No Yes Yes No Yes
efavirenz + lamivudine + tenofovir No Yes No No No No
emtricitabine + tenofovir Yes Yes Yes Yes No Yes
lamivudine + nevirapine + zidovudine No Yes No No Yes No
lamivudine + zidovudine Yes Yes Yes Yes Yes Yes
10 other FDCs 5 other FDCs
Anti TB Medicines
isoniazid + pyridoxine +
sulfamethoxazole + trimethoprim
No No No No No No
ethambutol + isoniazid + pyrazinamide +
rifampicin
Yes Yes No No No Yes
ethambutol + isoniazid + rifampicin Yes Yes No No No No
(Continued )
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Table 2. (Continued).
Iran Kenya Kosovo Latvia Nigeria Romania
isoniazid + pyrazinamide + rifampicin Yes Yes No No No Yes
isoniazid + rifampicin Yes Yes Yes No Yes Yes
4 other FDCs 1 other FDC
Antimalarial medicines including prevention
artemether + lumefantrine Yes Yes No No Yes No
artesunate + amodiaquine No No No No Yes No
artesunate + mefloquine No No No No No No
artesunate + pyronaridine
tetraphosphate
No No No No No No
dihydroartemisinin + piperaquine
phosphate
No Yes No No No No
sulfadoxine + pyrimethamine Yes Yes No No Yes No
7 other FDCs 1 other FDC 1 other FDC
Non-communicable diseases
Cardiovascular – Hypertension, etc
lisinopril + amlodipine No No No Yes No No
lisinopril + hydrochlorothiazide Yes No No No No No
telmisartan + amlodipine No No No Yes No No
telmisartan + hydrochlorothiazide No No No Yes No Yes
10 other FDCs 2 other FDCs 22 other FDCs
Diabetes
None 5 FDCs
available
No No No No 7 FDCs
available
Respiratory
budesonide + formoterol Yes Yes Yes Yes No Yes
23 other FDCs 5 other FDCs
Pain
None No No No No No 1 FDC available
South Africa Srpska Sudan Vietnam Zambia Zimbabwe
Infectious diseases
Antibiotics (Prevention malaria, etc)
sulfamethoxazole + trimethoprim Yes Yes Yes Yes Yes Yes
HIV FDCs
abacavir + lamivudine Yes Yes No No Yes Yes
dolutegravir + lamivudine + tenofovir Yes No No No Yes Yes
efavirenz + emtricitabine + tenofovir Yes No No No Yes Yes
efavirenz + lamivudine + tenofovir No No No Yes Yes Yes
emtricitabine + tenofovir Yes Yes No No Yes Yes
lamivudine + nevirapine + zidovudine No No No Yes Yes Yes
lamivudine + zidovudine Yes Yes No Yes Yes Yes
2 other FDCs 1 other FDC 2 other FDCs 1 other FDC
Anti TB Medicines
isoniazid + pyridoxine +
sulfamethoxazole + trimethoprim
No No No No No No
ethambutol + isoniazid + pyrazinamide
+ rifampicin
Yes Yes Yes Yes Yes Yes
ethambutol + isoniazid + rifampicin No Yes Yes Yes Yes Yes
isoniazid + pyrazinamide + rifampicin Yes No Yes Yes Yes Yes
isoniazid + rifampicin Yes Yes Yes Yes Yes Yes
1 other FDC 1 other FDC
Antimalarial medicines including prevention
artemether + lumefantrine Yes No Yes Yes Yes Yes
artesunate + amodiaquine No No No Yes No Yes
artesunate + mefloquine No No No Yes No No
artesunate + pyronaridine
tetraphosphate
No No No No No No
dihydroartemisinin + piperaquine
phosphate
No No No Yes No No
sulfadoxine + pyrimethamine No No No Yes Yes Yes
2 other FDCs
Non-communicable diseases
Cardiovascular – Hypertension, etc
lisinopril + amlodipine Yes No No Yes No No
lisinopril + hydrochlorothiazide Yes Yes No Yes No No
telmisartan + amlodipine Yes No No Yes No Yes
telmisartan + hydrochlorothiazide Yes No No Yes Yes Yes
17 other FDCs 7 other FDCs 1 other FDC 16 other FDCs 2 other FDCs 5 other FDCs
Diabetes
None 2 FDCs available 7 FDCs
available
NA 7 FDCs available No 1 FDC available
Respiratory
budesonide + formoterol Yes Yes Yes Yes No No
2 other FDCs 4 other FDCs 1 other FDC 5 other FDCs
Pain
None 3 FDCs available No No 15 FDCs available No No
FDC, Fixed dose combination; HIV, Human immunodeficiency virus; INN, International non-proprietary name; TB, tuberculosis
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Table 3. Positive clinical and economic (general) considerations associated with FDCs.
Clinical benefits associated with FDCs (general) Economic benefits (general) associated with FDCs
● Simplifies the treatment schedule – which can be particularly important in
LMICs where there are low literacy levels as seen in a number of sub-Saharan
African countries
● Easier to prescribe
● Improved adherence with reduced pill burden
● Minimal frequency of medicine consumption and reduced chances of patients
missing doses
● Potential to attain clinical goals more rapidly through complimentary additive
effects of the components and/or reduced titration times
● Potential for increased tolerability and/or fewer side-effects through the
combination of synergistic medicines
● Reduced chances of stockouts with FDCs versus the components especially for
FDCs containing multiple medicines; consequently, potentially improving
clinical outcomes
● Potential for reduced overall costs enhanced by synergism with lower
doses – potential for lower costs than the components enhanced if FDCs are
produced and procured at low cost aided by mass approaches to production,
packaging, and distribution
● Reduced space for storage and distribution/potentially reduced logistical costs
● Potential for improved shelf life
● Now seeing in countries that prices of FDCs cannot be higher than the costs of
the individual components (e.g. Slovenia) and may even be lower (e.g. India
and Zambia)
FDC, Fixed dose combination; HIV, Human immunodeficiency virus; INN, International non-proprietary name; TB, tuberculosis
Table 4. Positive clinical considerations with FDCs across disease areas.
Disease area Benefits of FDCs
Cardiovascular diseases including
hypertension
● Improved dose frequency and ease of administration help improve adherence especially where patients are on multiple
medicines due to existing co-morbidities – potentially improving disease management
● Potential for improved effectiveness by combining different treatments with different mechanisms of action, e.g. different
lipid-lowering treatments
● One component of an FDC may offset the side-effects seen with other components, e.g. ACE inhibitors offsetting one of
the major side effects associated with calcium channel blockers
● Potential for minimal adverse effects alongside improvement in disease management
● Improved long-term adherence through reduced pill burden especially important among aging populations, e.g. European
LMICs
Type 2 Diabetes Mellitus (T2DM) ● Potential for improved adherence through reduced pill burden – especially important in T2DM patients with multiple co-
morbidities to enhance adherence rates
● Improved disease control for patients with T2DM as well as potentially reducing complications through using medicines
with different mechanisms of action
● In some countries, helps increase the prescribing of metformin where this is a concern and SUs available in combination
with metformin
Respiratory diseases ● FDCs containing ICS/LABAs are seen as a standard of care for the maintenance of patients with asthma
● Improved acceptance of FDCs versus separate inhalers helped by easier administration
● Reduced doses of steroids where there are concerns with continued high doses of steroids for maintenance among
patients with asthma
● FDCs seen to improve the quality of life of patients with asthma through improved adherence and better maintenance of
disease targets
Pain ● Improved potential for pain management with FDCs with different mechanisms of action where concerns with abuse or
increased side-effects if the dose of one component is increased to manage the pain
● Multiple mechanisms for a broader effect
Malaria ● Improved effectiveness and treatment success
● Improved adherence to prescribed medicines enhanced by the potential for shortened duration of treatment
● Potential for decreased resistance using medicines with different mechanisms of action
● Potential for reduced costs
Tuberculosis (TB) ● FDCs may help prevent the emergence of resistant strains especially given the length and complexity of the treatment
regimens involved
● Increased effectiveness against resistant cases with medicines with different mechanisms of action
● Reduces the incidence of MDR-TB
● Synergism at lower doses
● Complex treatment regimen eased by FDCs thereby enhancing completion rates
● Dispersible FDCs for children easing administration
Human immunodeficiency virus
(HIV)
● FDCs containing medicines with different mechanisms of action typically improves treatment outcomes
● Synergism at lower doses
● FDCs may help prevent the emergence of resistant strains
● Increased effectiveness against resistant cases
● Combining tablets simplifies treatment regimens and standardizes doses prescribed aiding subsequent quality of care
● Patients are unable to default on specific medicines believed to be causing side-effects such as dizziness and drowsiness
seen with efavirenz
ACE, angiotensin-converting enzyme; FDC, Fixed Dose Combination; ICS/LABAs, Inhaled corticosteroids/long-acting β agonists; MDR-TB, Multidrug resistant TB; SU =
sulfonyl urea.
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Table 6. Clinical concerns regarding FDCs across disease areas.
Disease area Concerns with FDCs
Cardio Vascular (CV) diseases including
hypertension
● Reduces the ability to tailor treatment to individual patients especially where adverse effects are seen with the
prescribed FDC
● More limited options with FDCs versus individual components
● More difficult to adjust doses when needed potentially enhancing treatment inertia
● Potential for doubling doses of medicines if patients and prescribers are not fully aware of the constituents of
prescribed FDCs
● Clinical rationality of a number of CV FDCs with the potential for inadequate dosing and increasing costs
● Concerns with the bioequivalence and pharmacokinetics of some FDCs for CV diseases
Type 2 Diabetes Mellitus (T2DM ● More difficult to adjust doses thereby potentially reducing the ability to tailor treatment to individual patients
● More limited options with FDCs versus individual components
● Reduced positive effect of metformin on CV events with reduced doses of metformin or with metformin/sulfonyl urea
combinations
● Potential for doubling doses of medicines if patients and prescribers are not fully aware of the constituents of
prescribed FDCs
● Clinical rationality of a number of FDCs, e.g. metformin FDCs in India
● FDCs enhance the potential for polypharmacy, e.g. in Slovenia many patients with T2DM are typically on 4 or more INN
medicines which was not often seen before the availability of FDCs
Respiratory diseases ● Reduces the potential for effective management especially where there are concerns with the doses of steroids
administered – as a result, potential for over medication with steroids
● Patients may need to use different inhaler devices with different FDCs impacting on adherence in practice
● Increasing concerns with prescribing of LABA/ICS combinations in patients with COPD unless asthma-like symptoms
Pain ● Reduces the ability to tailor treatment to individual patients
● More difficult to adjust doses
● Potential for substance misuse if currently taking FDCs due to the subjective nature of pain
● Limited clinical justification for FDCs to treat pain among some of the coauthors
● Potential to enhance irrational prescribing
Malaria ● Potential concerns with tolerance to mefloquine FDCs
● Appreciable number of unapproved FDCs in some LMICs
● Concerns with the pharmacokinetic profile of some FDCs for malaria impacting on their effectiveness and safety
● Potential loss of effectiveness
● Potential development of drug resistance to one or more of the components leading to loss of therapeutic options
Tuberculosis (TB) ● Difficult to desensitize patients in the event of adverse effects
● Potential for increased adverse events
● Some constituents of FDCs may cause more adverse effects than the originators
● Potential quality issues when medicines are combined especially with rifampicin in FDCs for TB – consequently
vigilance is needed to monitor the quality of rifampicin as a key component of antimalarial FDCs given concerns with
certain rifampicin FDCs in countries such as South Africa
● Potential loss of effectiveness
● Potential development of drug resistance to one or more of the components leading to loss of therapeutic options
● The interaction between efavirenz as well as lopinavir, dolutegravir, raltegravir with bedaquiline is a problem for
patients with HIV who also have MDR-TB (especially in sub-Saharan Africa) – necessitating a switch to twice daily
nevirapine with separate companion tablets – antiretroviral FDCs without bedaquiline drug interactions are strongly
recommended in these patients
Human immunodeficiency virus (HIV) ● Difficult to desensitize patients in the event of adverse effects, with the potential for increased adverse events with
FDCs
● Some constituents of FDCs may cause more adverse effects than the originators necessitating careful monitoring of
patients
● Potential loss of effectiveness over time
● Potential development of drug resistance to one or more of the components leading to loss of therapeutic options
● Currently, no liquid formulation FDCs are available for pediatric patients
● Imperative to educate patients that FDCs cannot be crushed or dissolved to improve swallowing as bioequivalence will
be compromised
● Supply chain integrity is imperative to ensure a continuous supply of ARV FDCs for patients with interruptions in supply
associated with sub-clinical outcomes
CV, cardiovascular; FDC,Fixed Dose Combination; ICS/LABAs,Inhaled corticosteroids/long-acting β agonists; INN, International non-proprietary name; MDR-
TB, Multidrug-resistant TB.
Table 5. General concerns regarding FDC.
Clinical concerns associated with FDCs (general) Economic concerns (general) associated with FDCs
● Reduces the ability to titrate individual doses to the specific needs of patients
● Potential for overtreatment if physicians and patients are not fully aware of
the constituents of FDCs – especially important if patients are switched to
different FDCs
● FDCs can increase polypharmacy especially in patients with chronic NCDs
● Issues of pharmacokinetics in some FDCs including issues of dissolution,
absorption and drug:drug interactions
● Missing doses of an FDC has a greater impact than missing doses of one of the
medicines in the FDC
● Challenging to ascertain responsible medicine for ADRs – especially important
for pharmacovigilance
● Potentially appreciably higher prices for the FDC versus the cost of the
components combined
● Typically only available as ‘branded’ medicines in some countries and conse-
quently only available in private pharmacies rather than public facilities and
not in rural areas, e.g. Cameroon
ADRs, Adverse Drug Reactions; FDC, Fixed Dose Combination
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH 15
include in this perspective paper as well as help with
contextualization of the findings. This especially given the
paucity of health economic studies of FDCs in LMICs versus
high-income countries.
We are also aware that we did not include all LMICs.
However, we did include LMICs from across continents to
help address this. Overall, we believe our findings and sugges-
tions are robust providing direction for the future.
3. Conclusions
FDCs are valued across a range of disease areas as seen by the
number of FDCs listed in WHO and country EMLs (Table 2).
This reflects their value with improving disease management,
reducing adverse reactions and improving adherence rates.
This is despite only a limited number of pharmacoeconomic
analyses to date in high priority disease areas in LMICs versus
BOX 1. Potential initiatives that can be undertaken by key stakeholder groups to enhance the availability and prescribing of valued FDCs.
A) Clinical and other considerations
● Emphasize the importance of adherence to treatments especially for patients with chronic NCDs and how valued FDCs can help with this. Concurrent with
this, improve prescriber education about the benefits of valued FDCs starting in medical school and continuing post qualification – similarly for pharmacists
who are increasingly involved with patient education regarding their medicines and the importance of adherence to prescribed doses
● Possibly linked to this, the development of quality prescribing indicators potentially linked with financial rewards
● Pharmaceutical companies to provide robust clinical trial data demonstrating improved outcomes and adherence with FDCs versus the components
separately to aid listing in country/region reimbursement list/EML (such data when available can be incorporated into robust health technology
assessments of new FDCs)
● Investigate further the clinically meaningful benefits of the polypill especially for sub-Saharan Africa given the appreciable increase in morbidity and
mortality due to CV diseases in recent years in these countries
● Robustly considering any potential drug:drug interactions or increased adverse effects in patients with HIV subsequently developing chronic NCDs
(increasingly happening in sub-Saharan Africa) and prescribed FDCs – especially as this co-morbid population is likely to experience challenges with
medication adherence/polypharmacy
● The process from transitioning from individual medicines to FDCs should be carefully managed in terms of supply chain management (where problems
currently exist) to facilitate procurement at a central level (and hence procurement at lower prices) and subsequent distribution
● Appropriate patient counseling also needs to take place to optimize the process – with intensive adherence counseling still needed especially among
patients with limited education. In view of this, if appropriate create policies that enhance capacity within health-care systems that help spread correct
information and awareness regarding the value and effectiveness of pertinent FDCs as well as use patient organizations where these exist to spread key
messages – this can include instigating educational activities among physicians and pharmacists in medical and pharmacy schools and post-qualification
● Accelerating the registration/pricing procedures for valued FDCs in countries where this is a concern, e.g. Sudan. This can be addressed through the
provision of scientifically sound guidelines and robust data supporting their registration as well as a review of reimbursement/pricing procedures where
there are concerns
● More flexible approaches to private pharmacies regarding the availability of FDCs especially in rural areas where this is a concern, e.g. Cameroon
B) Economic
● Realistic pricing expectations and considerations especially where there are high patient co-payments or strict pricing regulations, e.g. Estonia, to help
overcome concerns with the over-pricing of FDCs and enhance their chances of being reimbursed/listed in national/regional EMLs – typically initially robust
health technology assessments using cost minimization approaches are needed among LMICs to enhance their listing in national EMLs (progressing to cost-
effectiveness analyses as sophistication levels grow)
● Addressing issues of affordability and access where these exist – including reducing additional patient co-payments for the FDC versus multiple tablets of
the same medicines where these exist especially for valued FDCs, e.g. Bulgaria and Poland
● Concurrent with this, promoting local pharmaceutical company participation in the manufacturing of FDCs to agreed quality standards through incentives
and other mechanisms to help address supply chain and affordability/access issues where these exist
Abbreviations: EML = Essential Medicine List; FDC = Fixed Dose Combination; LMICs = Lower- and Middle-Income countries; NCDs = Non-communicable
diseases
BOX 2. Potential initiatives that can be undertaken by key stakeholder groups to reduce or negate the availability of FDCs where concerns.
A) Clinical
● The development of public/private partnerships to help standardize treatment approaches including the prescribing of FDCs
● Provision of robust health technology assessments to support listing/funding of FDCs in LMICs – especially for more elderly patients with high pill burdens.
This includes robust cost-effectiveness analyses across LMICs demonstrating their value versus the prescribing of multiple medicines for the same patient
population
● Concomitant with this – greater focus on issues of potential polypharmacy with FDCs especially in elderly patients with multiple co-morbidities
● Only register FDCs of proven clinical value, enforced through tighter regulations – especially important in countries with existing high rates of irrational
FDCs, e.g. India – although changing – and to prevent the future availability of FDCs where concerns
● Improved education of undergraduates and physicians where concerns with irrational FDCs, e.g. India. This should be continued with activities after
qualification including in-service training/continual professional development to enhance adherence rates among patients to prescribed FDCs given
ongoing concerns with long-term adherence to medicines especially in patients with chronic asymptomatic conditions
● Improve pharmacovigilance activities especially for FDCs where there are safety as well as drug:drug interaction concerns
● Greater interaction and empowerment of national patient organizations to enhance the appropriate use of valued FDCs and limit the prescribing/use of
FDCs where there are clinical and other concerns
● Enforce legislation and monitor activities to reduce or negate non-prescription sales of FDCs especially where concerns with their rationality
B) Economic
● Tougher hurdles for pricing/reimbursement considerations to reduce reimbursement/listing of FDCs of limited clinical value as well as unjustifiably higher
prices than the components combined
FDC = Fixed Dose Combination; LMICs = Lower- and Middle-Income countries
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high-income countries to fully appraise whether FDCs are
pharmacoeconomically justified. Having said this, there are
a number of concerns with FDCs including increasing the
number of adverse reactions, reducing effectiveness in routine
clinical practice, encouraging imprecise diagnoses and increas-
ing costs which affect their overall value. Consequently, their
availability and use need to be carefully managed in routine
clinical care, with the use of FDCs enhanced by the availability
of robust clinical and economic data. A number of activities
are also needed to enhance their utility alongside more phar-
macoeconomic analyses. These include greater education of
physicians and patients of their value where pertinent along-
side activities to further improve adherence rates especially in
patients with chronic diseases. Concurrent with this, ongoing
activities including stricter regulations to limit the availability
and use of FDCs of limited value.
Overall, we are likely to see greater availability and use of
valued FDCs across LMICs in the future to improve patient care
as more evidence becomes available. This is especially impor-
tant in patients with infectious diseases such as HIV and TB as
well as NCDs including CV diseases and diabetes.
4. Expert opinion
We expect to see growing availability and use of FDCs in both
infectious and non-infectious disease areas in the future building
on their potential advantages. Advantages include improved
response rates when combined especially where there are side-
effect concerns at optimal doses of single agents. In addition,
improved adherence rates through more simplified dosing regi-
mens. Improved adherence rates are particularly important
where there are complex treatment regimens and where
patients are often on multiple medicines to help control their
disease. These advantages are recognized by the endorsement of
FDCs in priority disease areas by the WHO as well as by national
and regional governments in their lists of medicines available
within public health-care systems. FDCs can also be cost-
effective; however, there is a paucity of such data within LMICs.
There are though recognized disadvantages with FDCs.
These include the availability of irrational FDCs especially in
countries such as India and Nepal, although this is changing.
There are also concerns that the pharmacogenetics of patients
will not be taken into consideration in their development, con-
cerns with identifying which component is responsible for side-
effects when these occur, challenges with dose adjustments and
appreciable higher prices for the FDCs versus the separate
components. Higher prices can persist when the components
are available as lower-cost generics but the FDC prolongs the
patent life. Concerns with dose adjustments can be helped by
making multiple dosing forms available. We are likely to see an
increasing number of studies conducted in LMICs demonstrat-
ing the clinical and economic advantages of FDCs to address
such concerns. This will be helped by the growing capability of
LMICs to conduct robust health technology assessments espe-
cially middle-income countries. The listing of FDCs within reim-
bursement and procurement lists will also be helped by realistic
pricing versus the components separately. Pricing is particularly
important where there are high patient co-payments. We are
also likely to see improved regulatory standards to remove or
negate marketing authorization of FDCs of limited value, or
unapproved FDCs, building on previous initiatives in Europe
via the EMA and in the US via the FDA. This is already happening
in India leading to the removal of over 300 FDCs in recent years.
We are also likely to see educational initiatives to improve the
knowledge of FDCs among physicians, pharmacists, and
patients. This includes addressing concerns with over treatment
if physicians and patients are not fully aware of the components
of FDCs as well as helping with the transition from individual
medicines to FDCs where necessary especially for patients with
NCDs. Such activities are likely to be increasingly combined with
initiatives to enhance adherence rates to prescribed medicines
including educational activities and adherence clubs to further
improve patient care especially in patients with asymptomatic
chronic conditions. Consequently, as mentioned, we are likely to
see growing utilization of valued FDCs across LMICs in the future
especially with LMICs striving to achieve their SDGs. Alongside
this, an increasing number of publications undertaken in LMICs
demonstrating that FDCs are pharmacoeconomically sound
within a number of disease areas although there will continue
to be concerns with some of them.
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